Evidence map›Paper›PMID 21914486›Full record

ReviewNeurobiology of learning and memory2011

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

Sergio T Ferreira, William L Klein

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurobiology of learning and memory, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 228 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
228citing papers in PubMed, 4 pooled it
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

228 citing papers in PubMed, 4 syntheses or guidelines pooled it, 444 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. A small TAT-TrkB peptide prevents BDNF receptor cleavage and restores synaptic physiology in Alzheimer's disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  19. Review
  20. Article

168 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Sergio T FerreiraInstitute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-590, Brazil. ferreira@bioqmed.ufrj.br
William L Klein
Northwestern University · USUniversidade Federal do Rio de Janeiro · BR

Funding

Abeta oligomers (ADDLs)in Alzheimers Disease pathologyR01AG022547 · NIA · NORTHWESTERN UNIVERSITY · PI KLEIN, WILLIAM L · 2003 to 2010
$1.9M
ADDLs, synapses & the molecular etiology of Alzheimer's diseaseR01AG029460 · NIA · NORTHWESTERN UNIVERSITY · PI KLEIN, WILLIAM L · 2007 to 2009
$916k
NEUROLOGICAL DEFICITS DUE TO TOXIC A BETA OLIGOMERSR01AG018877 · NIA · NORTHWESTERN UNIVERSITY · PI KLEIN, WILLIAM L · 2001 to 2003
$890k
NIA NIH HHS R01 AG018877NIA NIH HHS R01 AG022547NIA NIH HHS R01 AG029460
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the 3rd most costly disease and the leading cause of dementia. It can linger for many years, but ultimately is fatal, the 6th leading cause of death. Alzheimer's disease (AD) is fatal and affected individuals can sometimes linger many years. Current treatments are palliative and transient, not disease modifying. This article reviews progress in the search to identify the primary AD-causing toxins. We summarize the shift from an initial focus on amyloid plaques to the contemporary concept that AD memory failure is caused by small soluble oligomers of the Aβ peptide, toxins that target and disrupt particular synapses. Evidence is presented that links Aβ oligomers to pathogenesis in animal models and humans, with reference to seminal discoveries from cell biology and new ideas concerning pathogenic mechanisms, including relationships to diabetes and Fragile X. These findings have established the oligomer hypothesis as a new molecular basis for the cause, diagnosis, and treatment of AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainHumansMemory DisordersNeuronsPlaque, AmyloidSynapsesAmyloid beta-Peptides

Identifiers

PMID21914486
PMCPMC4390395
OpenAlexW2051268743

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.